This post was originally published on this site NantKwest and ProMab Biotechnologies are collaborating to develop a novel immunotherapy for multiple myeloma using natural killer (NK) cells that target the B-cell maturation antigen, or BCMA. The therapy, called chimeric antigen receptor (CAR) NK-cell, is a tweaked version of the conventional CAR-T cell therapy: instead of isolating…
This post was originally published on this site A study reporting the case of a sarcoidosis patient infected with the bacteria Borrelia burgdorferi highlights the importance of maintaining an increased awareness about potential infectious conditions, such as Lyme disease, in patients with new onset of sarcoidosis. The case study, “Systemic Sarcoidosis Associated with Exposure to Borrelia burgdorferi…
This post was originally published on this site Chronic stress and the consequent release of the stress hormone epinephrine may help breast cancer cells grow by helping them get more energy, a study in mice shows. This effect might be reversed through treatment with vitamin C, researchers report. The study, “Stress-induced epinephrine enhances lactate dehydrogenase A…
This post was originally published on this site The U.S. Food and Drug Administration has granted accelerated approval to a combination of Tecentriq (atezolizumab) and the chemotherapy Abraxane (nab-paclitaxel) for patients with advanced triple-negative breast cancer, making this the first immunotherapy regimen approved specifically for breast cancer. The approval, which is for patients whose tumors produce…
This post was originally published on this site Researchers have developed an ultrasensitive diagnostic device, a kind of “lab-on-a-chip,” that quickly detects cancer using a droplet of blood, potentially allowing for an easier, cheaper, and more timely cancer diagnosis. The device is described in the study, “Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip,”…
This post was originally published on this site A combination of Kyprolis (carfilzomib) and dexamethasone, already approved for relapsed and refractory multiple myeloma, may also be effective and safe as a first-line treatment for newly diagnosed patients, according to a study. The dual combo yielded the highest response rates to date for a two-agent combination employed as…
This post was originally published on this site Madeline Collin, a 24-year-old activist with Gaucher disease, worries that patients like her will suffer deeply if Britain leaves the European Union (EU), as scheduled, at the end of this month. Collin is an expert on the subject. For her University of Bathdissertation, she analyzed Brexit’s long-term…
This post was originally published on this site The expansion stage of a Phase 1/2 trial testing tinostamustine in relapsed or refractory types of lymphoma and other blood cancers has enrolled a first patient. The study (NCT02576496) is currently enrolling up to 65 patients in the U.S. and Europe with advanced multiple myeloma, Hodgkin’s lymphoma, peripheral T-cell…
This post was originally published on this site TC BioPharm (TCB) and Trinity College Dublin researchers are working together to expedite the production of V delta 1 γδ T cells to be used in the fight against solid tumors. TCB’s in-house Good Manufacturing Practice (GMP) team will be working with Derek Doherty, an associate professor and head of immunology…
This post was originally published on this site Provenge (sipuleucel-T), a treatment approved in the U.S. for metastatic castration-resistant prostate cancer, significantly increased the number of patients alive at three years, compared to a placebo, a retrospective analysis of Phase 3 clinical data shows. The treatment, which harnesses the immune system to fight cancer, was…
